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Every day much energy is expended sorting out the tragedy 
that is childhood tuberculosis (TB). Given the other challenges 
faced by our public health services this is energy we can 
ill afford. It is unlikely that we shall have a more effective 
TB vaccine available before 2015. In the meantime, many 
cases of severe and complicated paediatric TB could be 
prevented by an effective programme of contact screening and 
chemoprophylaxis. This article looks at the ‘what, who and 
why’ of TB contact investigation and TB chemoprophylaxis, 
including some special cases. We ask why these activities are 
not happening and what can be done about the situation. 
Lastly, some proposals for improving the situation are made.
Some definitions
Chemoprophylaxis and preventive therapy are regimens for 
preventing the development of active TB disease in those with 
latent TB infection. In South Africa this is often referred to as 
‘TB prophylaxis’. It is important to note that it is intended to 
prevent disease in the infected, rather than prevent infection 
per se.
A close contact is someone living in the same household as a 
source case (e.g. the child’s caregiver) or someone in frequent 
contact with the source case.
TB contact investigation 
What investigations should be done?
Children who are household contacts should be screened 
for symptoms of disease. Tuberculin skin tests (TSTs) are 
recommended where available to screen for infection. Chest 
radiography is recommended where available to screen for 
TB disease. If it is not available, simple clinical assessment is 
sufficient to decide whether a contact is well or symptomatic, 
and consequently whether they need chemoprophylaxis, full 
work-up for TB disease or neither. Lack of resources is not an 
acceptable excuse for doing no screening at all.
Who should be investigated?
The risk of TB infection is greatest in children who have had 
close and prolonged contact with infectious TB cases. The risk 
of TB disease following infection is greatest in children who are 
younger (under 5 years old) and who were recently exposed 
(less than 2 years previously).1 Screening is therefore targeted 
at these groups. This does not mean that those who do not 
fall into these groups are not at risk. Screening should also be 
available for contacts of smear-negative pulmonary TB (PTB) 
cases. 
Why should TB investigation be carried out?
The main purpose of childhood contact screening is to identify 
young children with undiagnosed TB disease and provide 
them with preventive therapy so that their disease does not 
progress to severe and disseminated forms. 
TB prophylaxis
What should be offered?
The South African national tuberculosis programme (NTP)2 
currently recommends either a 6-month regimen of isoniazid 
(INH), 5 times a week, or 3 months of directly observed INH 
plus rifampicin (60/30), for all children who are household 
contacts of smear-positive PTB cases. It has been suggested 
that compliance with the latter regimen may be better as it is 
shorter. 
The WHO3 and most NTPs recommend INH, 5 mg/kg for 
6 months. Follow-up should be at least 2-monthly until the 
treatment is complete. The American Academy of Pediatrics4 
recommended somewhat higher doses (10 - 15 mg/kg) in its 
2004 position paper and recent local studies have supported 
this recommendation (P Donald – personal communication). 
The local recommendation may change.
What about the side-effects of INH?
It should be remembered that INH can and does commonly 
cause a number of ‘minor’ side-effects such as mild and 
transient headache, nausea and dizziness. These are unlikely 
to be detected in young children and infants but this does not 
mean they do not occur. In addition, the drug is well known 
to cause hepatotoxicity. Most commonly, an asymptomatic, 
transient elevation of transaminases may occur. Relatively 
rarely, a clinical hepatitis that resolves when INH is 
discontinued may occur. Very rarely, a fulminant hepatitis 
and liver failure may occur. Children at particular risk are 
those with pre-existing liver disease, malnourished children, 
and those receiving other potentially hepatotoxic drugs (e.g. 
anticonvulsant medications). 
Who should be offered TB prophylaxis?
There is agreement that all household contacts who are less 
than 5 years old and all who are HIV infected regardless of 
age should be offered chemoprophylaxis. What is less clear is 
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what to offer the child who is a close contact but aged 6 years, 
or who is 4 years old but only a casual contact. There should 
be sufficient flexibility in the NTP to allow caregivers, whether 
doctors or nurses, to make an assessment of the individual 
child’s risk and an evidence-based decision regarding the need 
for chemoprophylaxis rather than trying to enforce a rigid and 
arbitrary cut-off.
Why give TB prophylaxis?
A recent Cochrane Collaboration systematic review5 of the 
efficacy of INH prophylaxis in the prevention of TB confirmed 
that daily INH for 6 - 12 months reduces the occurrence of 
active TB over the follow-up period. The summary relative risk 
(RR) for developing TB was 0.4 (95% confidence interval (CI) 
0.31 - 0.52). The review also showed that INH is efficacious in 
preventing extrapulmonary TB (RR 0.34) and TB-specific (but 
not all-cause) mortality (RR 0.29). Most of those included in the 
review were admittedly not infants or young children.
Special circumstances
Where the contact is HIV-infected
If the child is otherwise well, it is recommended that INH 
prophylaxis be considered for all ages, including those aged 5 
years and older.  
Contacts of infectious multidrug-resistant (MDR) 
TB cases
The only chemoprophylaxis regimens studied are based on 
INH with or without rifampicin. MDR TB is resistant to both 
of these by definition, so it makes little sense to use them 
as prophylaxis for contacts of MDR cases. Instead, careful 
clinical follow-up for at least 2 years is recommended. The 
WHO3 does not currently recommend second-line drugs 
for chemoprophylaxis in such situations. The reader is also 
referred to the article by Schaaf6 in this series for further 
information on this issue.
Baby born to mother diagnosed with infectious PTB
Once the mother has been on effective treatment for 2 - 3 
weeks, she is generally no longer infectious. The risk is highest 
if the mother is diagnosed at the time of delivery or shortly 
thereafter. The baby and the placenta should be investigated 
for evidence of congenital TB infection. This is a difficult 
diagnosis to make and generally needs specialist referral. It 
should be emphasised that breastfeeding can be continued 
safely during this period, should this be the mother’s choice.
Breastfeeding infant with a mother with smear-
positive PTB
These infants are at very high risk of infection and disease. 
One of two regimens is recommended: either they should be 
offered 6 months of INH, followed by BCG immunisation; or 
3 months of INH, then a TST and, if negative, cessation of the 
INH and BCG, if positive, continuation of the INH for another 
3 months, after which it can be stopped and BCG given. Again, 
breastfeeding can be continued safely during this period. 
Why doesn’t it happen?
Given that we know it works, and we know how serious 
the consequences are of not protecting exposed infants and 
young children, one has to ask why so few childhood contacts 
in South Africa and other developing countries receive their 
chemoprophylaxis. The WHO3 position paper admits: ‘Close 
contact screening and management is recommended by most 
NTPs, but rarely happens in low-resource settings, where the 
majority of childhood TB occurs – although for the majority of 
child contacts assessment can be a straightforward procedure 
that simply requires clinical evaluation.’
Possible reasons for failure of the programme and possible 
obstacles to its implementation include: 
•    A lack of resources – a primary care clinic which is barely 
managing to cope with its load of acutely and chronically ill 
patients is unlikely to be able to commit human or physical 
resources to prevention. 
•    No provision for the management of contacts within the 
NTP, which understandably and rightly focuses on curing 
more than 85% of smear-positive patients. Exposed children 
are not seen as a priority within the NTP.
•    Children started on INH prophylaxis are usually not 
registered. There may or may not be a contact book but 
record keeping is likely to be suboptimal, which makes 
efficient programme management unlikely.
Proposed solutions
Some innovative suggestions, based on experiences in other 
developing countries, are proposed in the WHO3 paper. These 
include:
1.    Separate structures for contact screening and management. 
These structures would work within the existing NTP.
2.    Special ‘contact clinics’ at a set time and place each week 
where child contacts can be assessed. 
3.    The same health care worker who supervises the treatment 
of the source case to take responsibility for the management 
of the contacts of that source case. This is likely to be 
more convenient and acceptable for the family and lead to 
improved compliance.
4.    Adding an information box to the reverse side of the 
general TB treatment card to remind TB caregivers about 
the necessity of contact tracing and chemoprophylaxis. 
5.    Each child on prophylaxis to have her/his own TB 
prophylaxis card. 
6.    A separate registration book or register for children on TB 
prophylaxis. 
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Conclusion
Tracing infants and young children who are contacts of 
infectious TB cases and offering them chemoprophylaxis 
remains a relatively cheap and effective means of preventing 
the serious sequelae of childhood TB. In the absence of a more 
effective vaccine it should be given more prominence in TB 
control programmes in high-burden countries, including South 
Africa.
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